Related coverage linked through entity extraction aliases.
Apr 24, 2026
Tempus AI signed an agreement to provide precision medicine technology to the University of Southern California. USC will gain access to molecular diagnostics, genomic profiling, clinical trial matching and AI tools.
Apr 13, 2026
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Apr 12, 2026
Generative AI processed complex medical datasets faster than traditional teams in a preterm birth study, while the healthcare market for the technology reached US$2.92 billion in 2024. The market is projected to grow to US$30.68 billion by 2033 as adoption expands in clinical workflows, imaging, drug discovery and precision medicine.
Mar 20, 2026
The global AI in clinical trials market is expected to grow from $2.09 billion currently to $18.62 billion by 2040, driven by enhanced patient recruitment, optimized trial designs, and automation that reduces time and costs in drug development.
Mar 04, 2026
Tempus AI and Merck announced an expanded multi-year collaboration to accelerate discovery and development of precision medicine biomarkers using AI and multimodal datasets, focusing on oncology and potentially broader therapeutic areas.
Feb 14, 2026
Tempus AI partners with Median Technologies to integrate FDA-cleared eyonis LCS lung cancer screening software into its Pixel platform, marking the first US distribution agreement for the diagnostic tool.
